Literature DB >> 21086571

FOXP3 expression and clinical characteristics of hepatocellular carcinoma.

Wei-Hua Wang1, Chang-Li Jiang, Wei Yan, Yu-Hai Zhang, Jiang-Tao Yang, Cun Zhang, Bo Yan, Wei Zhang, Wei Han, Jun-Zhi Wang, Ying-Qi Zhang.   

Abstract

AIM: To study the biological and clinical characteristics of transcription factor forkhead box protein 3 (FOXP3) in hepatocellular carcinoma (HCC).
METHODS: We analyzed the expression and localization of FOXP3 in HCC tissues and cell lines to evaluate its biological features. The relationship between FOXP3 staining and clinical risk factors of HCC was assessed to identify the clinical characteristics of FOXP3 in HCC.
RESULTS: The mRNA and protein expression of FOXP3 were found in some hepatoma cell lines. Immunohistochemical (IHC) analysis of HCC sections revealed that 48% of HCC displayed FOXP3 staining, but we did not find any FOXP3 staining in normal liver tissues and para-tumor tissues. IHC and Confocal analysis showed that the expressions of FOXP3 were mainly present in the nucleus and cytoplasm of tumor cells in tissues or cell lines. In HCC, the distribution of FOXP3 was similar to that of the cirrhosis, but not to the hepatitis B virus. Those findings implicate that FOXP3 staining seems to be associated with the high risk of HCC.
CONCLUSION: The clinical characteristics of FOXP3 in HCC warrants further studies to explore its functions and roles in the cirrhosis and development of HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21086571      PMCID: PMC2988246          DOI: 10.3748/wjg.v16.i43.5502

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  22 in total

Review 1.  Foxp3: a critical regulator of the development and function of regulatory T cells.

Authors:  Shohei Hori; Shimon Sakaguchi
Journal:  Microbes Infect       Date:  2004-07       Impact factor: 2.700

2.  Stromal expression of fibroblast activation protein/seprase, a cell membrane serine proteinase and gelatinase, is associated with longer survival in patients with invasive ductal carcinoma of breast.

Authors:  N Ariga; E Sato; N Ohuchi; H Nagura; H Ohtani
Journal:  Int J Cancer       Date:  2001-01-20       Impact factor: 7.396

3.  Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.

Authors:  Lars A Ormandy; Tina Hillemann; Heiner Wedemeyer; Michael P Manns; Tim F Greten; Firouzeh Korangy
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 12.701

Review 4.  Viral hepatocarcinogenesis.

Authors:  W-L Tsai; R T Chung
Journal:  Oncogene       Date:  2010-03-15       Impact factor: 9.867

Review 5.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 6.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

7.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

Authors:  Andrew M Scott; Greg Wiseman; Sydney Welt; Alex Adjei; Fook-Thean Lee; Wendie Hopkins; Chaitan R Divgi; Lorelei H Hanson; Paul Mitchell; Denise N Gansen; Steven M Larson; James N Ingle; Eric W Hoffman; Paul Tanswell; Gerd Ritter; Leonard S Cohen; Peter Bette; Lisa Arvay; Andree Amelsberg; Dan Vlock; Wolfgang J Rettig; Lloyd J Old
Journal:  Clin Cancer Res       Date:  2003-05       Impact factor: 12.531

8.  Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.

Authors:  Firouzeh Korangy; Lars A Ormandy; Jörg S Bleck; Jürgen Klempnauer; Ludwig Wilkens; Michael P Manns; Tim F Greten
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

9.  Increased expression of seprase, a membrane-type serine protease, is associated with lymph node metastasis in human colorectal cancer.

Authors:  Satoshi Iwasa; Xin Jin; Kyoko Okada; Masako Mitsumata; Akishi Ooi
Journal:  Cancer Lett       Date:  2003-09-10       Impact factor: 8.679

10.  Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells.

Authors:  Haruhiko Yagi; Takashi Nomura; Kyoko Nakamura; Sayuri Yamazaki; Toshio Kitawaki; Shohei Hori; Michiyuki Maeda; Masafumi Onodera; Takashi Uchiyama; Shingo Fujii; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2004-10-04       Impact factor: 4.823

View more
  16 in total

1.  Osteopontin contributes to TGF-β1 mediated hepatic stellate cell activation.

Authors:  Xiao Xiao; Yi Gang; Yong Gu; Lina Zhao; Jindong Chu; Jinfeng Zhou; Xiqiang Cai; Hui Zhang; Li Xu; Yongzhan Nie; Kaichun Wu; Zhiguo Liu; Daiming Fan
Journal:  Dig Dis Sci       Date:  2012-06-04       Impact factor: 3.199

2.  IPEX Syndrome, FOXP3 and Cancer.

Authors:  Runhua Liu; Silin Li; Wei-Hsiung Yang; Lizhong Wang
Journal:  J Syndr       Date:  2013-06

3.  Osimertinib Improves the Immune Microenvironment of Lung Cancer by Downregulating PD-L1 Expression of Vascular Endothelial Cells and Enhances the Antitumor Effect of Bevacizumab.

Authors:  Xuejun Xiao; Yang Wu; Fang Shen; Yusufu MuLaTiAize; Nabi Xinhua
Journal:  J Oncol       Date:  2022-06-23       Impact factor: 4.501

4.  Expression of tumoral FOXP3 in gastric adenocarcinoma is associated with favorable clinicopathological variables and related with Hippo pathway.

Authors:  Jung-Ho Suh; Kyu Yeoun Won; Gou Young Kim; Go Eun Bae; Sung-Jig Lim; Ji-Youn Sung; Yong-Koo Park; Youn Wha Kim; Juhie Lee
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

5.  FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.

Authors:  BeeShin Tan; Matthew Anaka; Siddhartha Deb; Claudia Freyer; Lisa M Ebert; Anderly C Chueh; Sheren Al-Obaidi; Andreas Behren; Aparna Jayachandran; Jonathan Cebon; Weisan Chen; John M Mariadason
Journal:  Oncotarget       Date:  2014-01-15

6.  Bee venom phospholipase A2 protects against acetaminophen-induced acute liver injury by modulating regulatory T cells and IL-10 in mice.

Authors:  Hyunseong Kim; Dong June Keum; Jung won Kwak; Hwan-Suck Chung; Hyunsu Bae
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

Review 7.  Cholangiocarcinoma with respect to IgG4 Reaction.

Authors:  Kenichi Harada; Yasuni Nakanuma
Journal:  Int J Hepatol       Date:  2014-07-15

8.  Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer.

Authors:  Mia Kim; Tanja Grimmig; Martin Grimm; Maria Lazariotou; Eva Meier; Andreas Rosenwald; Igor Tsaur; Roman Blaheta; Uwe Heemann; Christoph-Thomas Germer; Ana Maria Waaga-Gasser; Martin Gasser
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

9.  Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomach.

Authors:  M Yoshii; H Tanaka; M Ohira; K Muguruma; T Iwauchi; T Lee; K Sakurai; N Kubo; M Yashiro; T Sawada; K Hirakawa
Journal:  Br J Cancer       Date:  2012-04-19       Impact factor: 7.640

10.  High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment.

Authors:  G-F Ma; Q Miao; Y-M Liu; H Gao; J-J Lian; Y-N Wang; X-Q Zeng; T-C Luo; L-L Ma; Z-B Shen; Y-H Sun; S-Y Chen
Journal:  Br J Cancer       Date:  2014-02-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.